Vitura Health Limited (formerly Cronos Australia Limited) is an ASX-listed company. Its subsidiaries include Burleigh Heads Cannabis, which operates the online platform CanView. CanView offers over 230 product SKUs from more than 30 medicinal cannabis producers, both domestic and international, within Australia. CDA Clinics offers nationwide telehealth consultations for patients seeking access to medicinal cannabis. Vitura Health also has joint ventures, including Cortexa Pty Ltd, where it holds 50% ownership, for supplying psychedelics, and owns a 75.5% stake in Cannadoc Health Pty Ltd, a medicinal cannabis clinic providing telehealth consultations nationwide.
Vitura Health (ASX: VIT)
- Home
- Vitura Health (ASX: VIT)
Here are the latest articles on Vitura Health (ASX: VIT)
Vitura’s Cortexa becomes first Aus company to supply ecstasy and magic mushrooms under TGA’s prescriber scheme
March 18, 2024
In July last year, Australia became the first country to legalise ecstasy (MDMA) and magic mushrooms (psilocybin) for mental health disorders, including PTSD and depression. A bold move, it spurred medical businesses into action, seeking the proper approvals and getting the early advantage. At the same time, not all medical professionals were so thrilled, citing
Vape imports banned, Vitura introduces nicotine vaping products to tap new market
January 10, 2024
In a bid to crack down on excessive vaping among the Aussie youth, the Australian government decided to nip the problem in the bud. From January 1, 2024, the Therapeutic Goods Administration (TGA) declared that disposable vapes can’t be imported to Australia, regardless of nicotine or therapeutic claims. Plus, come March 1, 2024, importing all
Vitura receives first MDMA for its newly-minted psychedelics arm Cortexa
November 8, 2023
In May 2023, diversified digital health company Vitura Health (ASX: VIT) announced a joint venture with Canadian psychedelic company PharmAla Biotech, giving birth to its Melbourne-based psychedelics arm, Cortexa. Providing an update on the 50-50 venture, the Company has noted an “Australian first” win. Its MDMA bulk GMP (good manufacturing practice) Active Pharmaceutical Ingredient (API)
From cannabis to telehealth, Vitura expands portfolio with $25m Doctors on Demand acquisition
October 19, 2023
Bringing pharmaceutical weed to telehealth, medical cannabis company Vitura Health (ASX: VIT) has decided to acquire telehealth company Doctors on Demand for an aggregate consideration of $25 million. This deal includes an upfront cash payment, a deferred cash component, and an equity stake. The acquisition marks Vitura’s leap into new healthcare verticals, including urgent care,
Vitura declares dividend for the second time amid growing cannabis profits
August 23, 2023
Once again, medical cannabis producer Vitura Health (ASX: VIT) has become the only ASX-listed company operating in the medicinal cannabis space to both generate a profit and declare a dividend since its ASX initiation in 2019. The Company will pay a dividend to shareholders in respect of FY23. The Dividend, which will be paid at
Vitura Health brand overhaul spells success story with successful results
February 14, 2023
Leading cannabis company providing a safe and reliable source of cannabis treatment products, Vitura Health (ASX: VIT) has released its financial results for the first half of FY2023, revealing a significant step up across the board following their recent business overhaul finalised earlier this year. You may not recognise the Company or its name just
Recent Articles
